Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease

다국어 초록 (Multilingual Abstract)

Background/Aims: Crosstalk between the gut microbiota and bile acid plays an important role in the pathogenesis of gastrointestinal disorders. We investigated the relationship between microbial structure and bile acid metabolism in the ileal mucosa of Crohn’s disease (CD).Methods: Twelve non-CD controls and 38 CD patients in clinical remission were enrolled. Samples were collected from the distal ileum under balloon-assisted enteroscopy. Bile acid composition was analyzed by liquid chromatography-mass spectrometry. The gut microbiota was analyzed by 16S rRNA gene sequencing.Results: The Shannon evenness index was significantly lower in endoscopically active lesions than in non-CD controls. β-Diversity, evaluated by the UniFrac metric, revealed a significant difference between the active lesions and non-CD controls (<i>P</i>=0.039). The relative abundance of <i>Escherichia</i> was significantly higher and that of <i>Faecalibacterium</i> and <i>Roseburia</i> was significantly lower in CD samples than in non-CD controls. The increased abundance of <i>Escherichia</i> was more prominent in active lesions than in inactive lesions. The proportion of conjugated bile acids was significantly higher in CD patients than in non-CD controls, but there was no difference in the proportion of primary or secondary bile acids. The genera <i>Escherichia</i> and <i>Lactobacillus</i> were positively correlated with the proportion of conjugated bile acids. On the other hand, <i>Roseburia</i>, <i>Intestinibacter</i>, and <i>Faecalibacterium</i> were negatively correlated with the proportion of conjugated bile acids.Conclusions: Mucosa-associated dysbiosis and the alteration of bile acid composition were identified in the ileum of CD patients. These may play a role in the pathophysiology of ileal lesions in CD patients.

참고문헌 (Reference)

1 Kaplan GG, "Understanding and preventing the global increase of inflammatory bowel disease" 152 : 313-321, 2017

2 Goldsmith JR, "The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications" 49 : 785-798, 2014

3 Sheehan D, "The microbiota in inflammatory bowel disease" 50 : 495-507, 2015

4 Begley M, "The interaction between bacteria and bile" 29 : 625-651, 2005

5 Mak WY, "The epidemiology of inflammatory bowel disease : east meets west" 35 : 380-389, 2020

6 Nagayama M, "TH1 cell-inducing Escherichia coli strain identified from the small intestinal mucosa of patients with Crohn’s disease" 12 : 1788898-, 2020

7 Shoda J, "Similarity of unusual bile acids in human umbilical cord blood and amniotic fluid from newborns and in sera and urine from adult patients with cholestatic liver diseases" 29 : 847-858, 1988

8 Nagalingam NA, "Role of the microbiota in inflammatory bowel diseases" 18 : 968-984, 2012

9 Hasegawa M, "Regulation of the gut microbiota by the mucosal immune system in mice" 26 : 481-487, 2014

10 Takahashi K, "Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease" 93 : 59-65, 2016

11 Lloyd-Price J, "Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases" 569 : 655-662, 2019

12 Sartor RB, "Microbial influences in inflammatory bowel diseases" 134 : 577-594, 2008

13 Schloss PD, "Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities" 75 : 7537-7541, 2009

14 Baumgart DC, "Inflammatory bowel disease : clinical aspects and established and evolving therapies" 369 : 1641-1657, 2007

15 Johansson ME, "Immunological aspects of intestinal mucus and mucins" 16 : 639-649, 2016

16 Lavelle A, "Gut microbiota-derived metabolites as key actors in inflammatory bowel disease" 17 : 223-237, 2020

17 Nishida A, "Gut microbiota in the pathogenesis of inflammatory bowel disease" 11 : 1-10, 2018

18 Franzosa EA, "Gut microbiome structure and metabolic activity in inflammatory bowel disease" 4 : 293-305, 2019

19 Ananthakrishnan AN, "Epidemiology and risk factors for IBD" 12 : 205-217, 2015

20 Litvak Y, "Dysbiotic Proteobacteria expansion : a microbial signature of epithelial dysfunction" 39 : 1-6, 2017

21 Sinha SR, "Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation" 27 : 659-670, 2020

22 Frank DN, "Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases" 17 : 179-184, 2011

23 Best WR, "Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study" 70 : 439-444, 1976

24 Murakami M, "Detection of gut dysbiosis due to reduced Clostridium subcluster XIVa using the fecal or serum bile acid profile" 24 : 1035-1044, 2018

25 Ridlon JM, "Consequences of bile salt biotransformations by intestinal bacteria" 7 : 22-39, 2016

26 Duboc H, "Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease" 62 : 531-539, 2013

27 Litvak Y, "Colonocyte metabolism shapes the gut microbiota" 362 : eaat9076-, 2018

28 Jia W, "Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis" 15 : 111-128, 2018

29 Costello EK, "Bacterial community variation in human body habitats across space and time" 326 : 1694-1697, 2009

30 Nishino K, "Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease" 53 : 95-106, 2018